UniQure dips after share sale swells to $225 mln
BUZZ-UniQure dips after share sale swells to $225 mln ** U.S.-listed shares of Dutch drugmaker uniQure NV QURE.O down 1.1% to $48.51 on Weds after $225 mln follow-on offering priced
** QURE sold ~4.9 mln shares at $45.50, a 7.2% discount to stock's last sale on Tues
** Offering size increased from $150 mln
** QURE shares surged 78% last Weds after U.S. FDA reversed its earlier position and said it will accept existing trial data for an accelerated review of co's Huntington's disease therapy, AMT-130
** QURE intends to use net offering proceeds to fund potential commercial launches of AMT-130, and to develop other product candidates, among other purposes, per the prospectus
** Leerink Partners, Stifel, Guggenheim and RBC acting as joint bookrunners
** U.S.-listed shares have doubled YTD. They were trading around $14 a year ago
** 13 of 15 analysts rate the shares "strong buy" or "buy", 2 "hold"; median PT $60.50, per LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal